GlassScriptPhysician profile
Bevi Leigh Wilson
NPI 1376112284
$5,005.90
in general payments reported to CMS, 2019-2025
26 companies · $656 in 2025
The $656 reported for 2025 was more than what 80% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $867 · 2022: $495 · 2023: $515 · 2024: $2,473 · 2025: $656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,767 · Travel and Lodging: $877.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,767.34 |
| Travel and Lodging | $876.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nalu Medical, INC. | $1,302.42 | 2023-2024 | Nalu Neurostimulation System |
| Nevro Corp. | $700.67 | 2023-2024 | Senza |
| Globus Medical, INC. | $500.45 | 2025 | Senza, Vyrsa Fix, Vyrsa V1 |
| Novo Nordisk INC | $257.14 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $244.59 | 2021-2024 | Relistor |
| Boston Scientific Corporation | $192.77 | 2023-2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $186.26 | 2021-2024 | Zepbound |
| Astrazeneca Pharmaceuticals LP | $183.78 | 2021-2023 | Farxiga |
| Medtronic, INC. | $182.59 | 2023-2025 | Vectris Surescan, Synchromedii |
| Aurinia Pharma U.S., INC. | $137.47 | 2023 | Lupkynis |
| Horizon Therapeutics Plc | $131.94 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.82 | 2021 | |
| Collegium Pharmaceutical, INC. | $115.75 | 2023-2024 | Belbuca |
| Corcept Therapeutics | $114.40 | 2022 | |
| Averitas Pharma INC. | $88.01 | 2024-2025 | Qutenza |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $84.24 | 2024 | |
| Esperion Therapeutics, INC. | $83.87 | 2021 | |
| Amgen INC. | $83.57 | 2021 | |
| Amarin Pharma, INC. | $58.26 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.86 | 2021 | |
| Abbvie INC. | $49.10 | 2022-2023 | |
| Vifor Pharma, INC. | $45.18 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $42.64 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $23.29 | 2022 | |
| Fresenius USA Marketing, INC. | $13.17 | 2023 | Velphoro, Korsuva |
| Glaxosmithkline, LLC. | $12.66 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bevi Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.